Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00625898Phase 3Terminated

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Role: collaborator

NCT00021255Phase 3Completed

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Role: collaborator

NCT00312208Phase 3Completed

Docetaxel in Breast Cancer

Role: collaborator

NCT00688740Phase 3Completed

Docetaxel in Node Positive Adjuvant Breast Cancer

Role: collaborator

NCT00637026Phase 2Completed

Ph II Early BC Pre-Surgical Biologic Study

Role: collaborator

All 5 trials loaded